GAPDH and neoplasm: However, in more recent years, some anti-tumor drugs under investigation are involving tumor metabolism, e.g. by reducing glucose availability as metformin [35], or by directly targeting glycolysis proteins [36]; our results suggest that in clinical investigations on these drugs, GAPDH levels in resected NSCLC samples should be investigated as possible predictor of treatment effectiveness.